Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1689180

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what comparative assessment she has made of trends in the total number of medicine shortages recorded by her Department in January (a) 2021, (b) 2022, (c) 2023 and (d) 2024.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	14113
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>There are around 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex and global, and supply disruption is a common issue which affects countries all around the world.</p><p>The Department’s medicine Discontinuations and Shortages portal has been collecting notifications from suppliers of potential supply issues since October 2020, and shows that there were approximately:</p><p>- 90 supply issue notifications in January 2021;</p><p>- 110 supply issue notifications in January 2022;</p><p>- 170 supply issue notifications in January 2023; and</p><p>- 160 supply issue notifications in January 2024.</p><p>Although reporting does vary each month, annual notifications have remained fairly stable at approximately 1,600 supply issue notifications in 2022 and 2023. It is important to note that not all supply issue notifications will lead to a medicine shortage.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/02/2024 11:24:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1689181

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Parkinson's Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	14114
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14115 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1689182

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Parkinson's Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	14115
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14114 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1685842

	registered interest
	date	30/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to tackle medicine shortages.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	12074
	answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>There are around 14,000 licensed medicines and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global, meaning there can sometimes be supply issues which affect the United Kingdom, along with other countries around the world.</p><p>Medicine supply problems can occur for several reasons such as manufacturing difficulties, regulatory non-compliance, access to raw materials, sudden demand spikes or distribution issues.</p><p>While it is not always possible to prevent supply issues from occurring, there is a team within the Department that has a range of well-established tools and processes to manage them when they arise, working closely with the pharmaceutical industry, the National Health Service, the Medicines and Healthcare products Regulatory Agency and others operating in the supply chain to help mitigate the risks to patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/02/2024 15:39:06 answering member 4044 label Biography information for Andrew Stephenson previous answer version 15319 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi